Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $25.30 is 1,204.12% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 25.48||$ 28|
|Low:||$ 24.13||$ 1.94|
ETFs with AXSM as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|1.33%||Invesco DWA SmallCap Momentum ETF (DWAS)||+3.33 (6.47%)|
|1.33%||Invesco DWA Tactical Multi-Asset Income ETF (DWIN)||+0.85 (3.46%)|
|*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past 100 days.|
Company Description (as filed with the SEC)
We are a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system, or CNS, disorders for which there are limited treatment options. By focusing on this therapeutic area, we are addressing significant and growing markets where current treatment options are limited or inadequate. Our core CNS portfolio includes four CNS product candidates, AXS05, AXS-07, AXS-09, and AXS-12, which are being developed for multiple indications. We are conducting a Phase 3 trial with AXS-05 in treatment resistant depression, or TRD, which we refer to as the STRIDE-1 study, a Phase 2/3 trial in agitation associated with Alzheimer's disease, or AD, which we refer to as the ADVANCE-1 study. Additionally, AXS-05 is currently in a Phase 2 trial in smoking cessation and we recently completed a Phase 2 trial in major depressive disorder, or MDD, which we refer to as the ASCEND study. ... More ...
Nasdaq Official Price
Jul. 18, 2019
Jul. 18, 2019